Google sign-in. No card required.
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity
As we expand globally, the Intercontinental (ICON) region represents a strategically important opportunity for clinical development, patient access and future commercialization. This is a unique leadership opportunity to establish and lead Revolution Medicines’ Corporate Affairs capability across Japan, Canada, Australia, Brazil and the broader ICON region. Reporting to the Senior Vice President, Corporate Affairs, with a dotted line to the Senior Vice President, Intercontinental (ICON), the Executive Director, Corporate Affairs, Intercontinental will shape the company’s external presence and help create the conditions for sustainable growth across the region.
Working as a partner to the ICON leadership team and country General Managers, this leader will be responsible for developing an integrated regional Corporate Affairs strategy across external and internal communications and corporate reputation. The role will help shape healthcare environments that improve cancer outcomes, strengthen healthcare systems and enable timely access to innovation. It will translate global priorities into locally relevant strategies while ensuring country perspectives inform enterprise decisions.
Success in the Role
Within the first 24–36 months, the successful leader will:
-
Establish an integrated ICON strategy and scalable Corporate Affairs network with clear country priorities, accountabilities and measures of impact.
-
Deliver coordinated corporate and launch communications, supported by effective stakeholder governance, issues management and crisis preparedness.
-
Build trusted relationships with industry associations, strengthening the company’s reputation and understanding of patient needs.
-
Support oncology innovation, clinical research and timely, equitable access to precision medicines.
Key Responsibilities
Strategic and Regional Leadership
-
Develop and execute the ICON Corporate Affairs strategy, aligning global objectives with country priorities, market maturity and launch timing.
-
Advise regional leaders and country General Managers on reputational developments; bring country insights into global planning and decision-making forums.
-
Set annual priorities, budgets and performance measures; build a lean operating model with clear responsibilities across global, regional and country teams.
-
Recruit and develop talent as needs evolve; select and manage specialist partners, setting expectations for quality, impact, budget discipline and ethical conduct. Equip countries with practical guidance and share effective approaches.
Corporate Communications and Reputation
-
Develop a coherent regional narrative connecting the company’s science, patient purpose and local contribution; adapt global messaging for local audiences across media, digital and company channels.
-
Partner with the Global Head of Communications to ensure ICON communications advance the global corporate narrative, scientific leadership and reputation priorities, while reflecting local market needs.
-
Build media relationships and lead proactive and reactive communications with Global Communications and country leaders. In part